TENX
Income statement / Annual
Last year (2023), Tenax Therapeutics, Inc.'s total revenue was $0.00,
and the percentage change from the previous year is not available.
In 2023, Tenax Therapeutics, Inc.'s net income was -$7.71 M.
See Tenax Therapeutics, Inc.’s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
FY-2015
|
FY-2014
|
| Period Ended |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
04/30/2015 |
04/30/2014 |
| Operating Revenue |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$49,286.00
|
$288,726.00
|
| Cost of Revenue |
$7,570.00 |
$113,332.00 |
$108,982.00 |
$114,748.00 |
$107,279.00 |
$9,015.00 |
$13,621.00 |
$18,952.00 |
$9,727.30 |
$129,800.00 |
| Gross Profit |
-$7,570.00 |
-$113,332.00 |
-$108,982.00 |
-$114,748.00 |
-$107,279.00 |
-$9,015.00 |
-$13,621.00 |
-$18,952.00 |
$39,558.00 |
$158,926.00 |
| Gross Profit Ratio |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0.8 |
0.55 |
| Research and Development
Expenses |
$3.23 M
|
$5.38 M
|
$25.15 M
|
$4.56 M
|
$3.47 M
|
$1.24 M
|
$3.53 M
|
$13.14 M
|
$6.66 M
|
$3.00 M
|
| General & Administrative
Expenses |
$5.01 M
|
$5.68 M
|
$7.58 M
|
$5.31 M
|
$5.08 M
|
$5.65 M
|
$5.68 M
|
$6.25 M
|
$7.17 M
|
$13.77 M
|
| Selling & Marketing
Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General &
Administrative Expenses |
$5.01 M
|
$5.68 M
|
$7.58 M
|
$5.31 M
|
$5.08 M
|
$5.65 M
|
$5.68 M
|
$6.25 M
|
$7.17 M
|
$13.77 M
|
| Other Expenses |
$0.00 |
$9,191.00 |
$254,832.00 |
$18,166.00 |
$160,901.00 |
$79,835.00 |
$366,216.00 |
$33.27 M |
$1.03 M |
$1.03 M |
| Operating Expenses |
$8.23 M |
$11.05 M |
$32.73 M |
$9.87 M |
$8.56 M |
$6.89 M |
$9.21 M |
$19.39 M |
$13.83 M |
$16.77 M |
| Cost And Expenses |
$8.23 M |
$11.05 M |
$32.73 M |
$9.87 M |
$8.56 M |
$6.89 M |
$9.21 M |
$19.39 M |
$13.83 M |
$16.90 M |
| Interest Income |
$0.00 |
$4.44 |
$0.95 |
$31,000.00 |
$144,000.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
| Interest Expense |
$23,967.00 |
$4,443.00 |
$949.00 |
$1,627.00 |
$0.00 |
$0.00 |
$0.00 |
$32.50 M |
$49,081.00 |
$2.21 M |
| Depreciation &
Amortization |
$7,570.00
|
$113,332.00
|
$108,982.00
|
$114,748.00
|
$107,279.00
|
$9,015.00
|
$13,621.00
|
$18,952.00
|
$148,140.00
|
$150,489.00
|
| EBITDA |
-$8.23 M
|
-$10.93 M
|
-$32.36 M
|
-$9.74 M
|
-$8.29 M
|
-$6.88 M
|
-$9.19 M
|
-$51.87 M
|
-$15.59 M
|
-$13.88 M
|
| EBITDA Ratio |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
-276.63 |
-57.01 |
| Operating Income Ratio
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
-300.63
|
-57.53
|
| Total Other
Income/Expenses Net |
$523,267.00
|
$4,748.00
|
$253,883.00
|
$16,539.00
|
$160,901.00
|
$79,835.00
|
$366,216.00
|
$764,735.00
|
$536,301.00
|
-$392,530.00
|
| Income Before Tax |
-$7.71 M |
-$11.05 M |
-$32.47 M |
-$9.85 M |
-$8.39 M |
-$6.81 M |
-$8.84 M |
-$51.89 M |
-$14.08 M |
-$19.54 M |
| Income Before Tax Ratio
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
-285.72
|
-67.68
|
| Income Tax Expense |
$0.00 |
-$4,748.00 |
$255,781.00 |
$19,793.00 |
-$64,581.00 |
-$79,835.00 |
-$366,216.00 |
-$7.96 M |
$250,851.00 |
$718,436.00 |
| Net Income |
-$7.71 M |
-$11.04 M |
-$32.73 M |
-$9.87 M |
-$8.39 M |
-$6.73 M |
-$8.84 M |
-$43.92 M |
-$14.08 M |
-$19.54 M |
| Net Income Ratio |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
-285.72 |
-67.68 |
| EPS |
-31.09 |
-600.46 |
-2545.11 |
-1523.8 |
-27.1 |
-7359.14 |
-10022.32 |
-624.82 |
-200.61 |
-834.94 |
| EPS Diluted |
-31.04 |
-600.46 |
-2545.11 |
-1523.8 |
-27.1 |
-7359.14 |
-10022.32 |
-624.82 |
-200.61 |
-834.94 |
| Weighted Average Shares
Out |
$248,000.00
|
$18,391.00
|
$12,860.00
|
$6,478.00
|
$309,772.00
|
$915.00
|
$882.00
|
$70,299.00
|
$70,194.00
|
$23,405.00
|
| Weighted Average Shares
Out Diluted |
$248,447.00
|
$18,391.00
|
$12,860.00
|
$6,478.00
|
$309,772.00
|
$915.00
|
$882.00
|
$70,299.00
|
$70,194.00
|
$23,405.00
|
| Link |
|
|
|
|
|
|
|
|
|
|
